JP2025513289A5 - - Google Patents
Info
- Publication number
- JP2025513289A5 JP2025513289A5 JP2024561602A JP2024561602A JP2025513289A5 JP 2025513289 A5 JP2025513289 A5 JP 2025513289A5 JP 2024561602 A JP2024561602 A JP 2024561602A JP 2024561602 A JP2024561602 A JP 2024561602A JP 2025513289 A5 JP2025513289 A5 JP 2025513289A5
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- approximately
- patient
- amino acid
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263333287P | 2022-04-21 | 2022-04-21 | |
| US63/333,287 | 2022-04-21 | ||
| US202263381752P | 2022-10-31 | 2022-10-31 | |
| US63/381,752 | 2022-10-31 | ||
| PCT/US2023/019448 WO2023205447A2 (en) | 2022-04-21 | 2023-04-21 | Uses of farnesoid x receptor agonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025513289A JP2025513289A (ja) | 2025-04-24 |
| JP2025513289A5 true JP2025513289A5 (https=) | 2026-04-28 |
Family
ID=88420596
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024561602A Pending JP2025513289A (ja) | 2022-04-21 | 2023-04-21 | ファルネソイドｘ受容体アゴニストの使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250288600A1 (https=) |
| EP (1) | EP4511012A2 (https=) |
| JP (1) | JP2025513289A (https=) |
| KR (1) | KR20250006156A (https=) |
| CN (1) | CN119136794A (https=) |
| AU (1) | AU2023257308A1 (https=) |
| CA (1) | CA3249500A1 (https=) |
| IL (1) | IL315941A (https=) |
| MX (1) | MX2024012966A (https=) |
| WO (1) | WO2023205447A2 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4611888A1 (en) * | 2022-10-31 | 2025-09-10 | Intercept Pharmaceuticals, Inc. | Uses of farnesoid x receptor agonists |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112017004708A2 (pt) * | 2014-09-12 | 2017-12-05 | Tobira Therapeutics Inc | terapia de combinação de cenicriviroc para o tratamento de fibrose |
| PE20180690A1 (es) * | 2015-04-27 | 2018-04-23 | Intercept Pharmaceuticals Inc | Composiciones de acido obeticolico y metodos de uso |
| ES2874682T3 (es) * | 2016-03-11 | 2021-11-05 | Intercept Pharmaceuticals Inc | Derivados de 3-desoxi y composiciones farmacéuticas de los mismos |
| BR112019027458A2 (pt) * | 2017-06-23 | 2020-07-07 | Intercept Pharmaceuticals, Inc. | métodos e intermediários para a preparação de derivados de ácidos biliares |
-
2023
- 2023-04-21 WO PCT/US2023/019448 patent/WO2023205447A2/en not_active Ceased
- 2023-04-21 AU AU2023257308A patent/AU2023257308A1/en active Pending
- 2023-04-21 US US18/858,674 patent/US20250288600A1/en active Pending
- 2023-04-21 IL IL315941A patent/IL315941A/en unknown
- 2023-04-21 CA CA3249500A patent/CA3249500A1/en active Pending
- 2023-04-21 JP JP2024561602A patent/JP2025513289A/ja active Pending
- 2023-04-21 KR KR1020247038272A patent/KR20250006156A/ko active Pending
- 2023-04-21 EP EP23792602.7A patent/EP4511012A2/en active Pending
- 2023-04-21 CN CN202380035124.0A patent/CN119136794A/zh active Pending
-
2024
- 2024-10-21 MX MX2024012966A patent/MX2024012966A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020186241A (ja) | 酸素化コレステロール硫酸塩（ｏｃｓ）の使用 | |
| US20040242491A1 (en) | Composition containing dipeptide of histidine and alanine for reducing uric acid and method for reducing uric acid using the dipeptide | |
| JP7578243B2 (ja) | アルカリ性化剤による血液浄化 | |
| JP2023115271A5 (https=) | ||
| JP2009511576A (ja) | ロイシンに富む組成物 | |
| JP2025513289A5 (https=) | ||
| WO2022042541A1 (zh) | 眼镜蛇蛇毒或其提取物在制备降尿酸和/或抗痛风性关节炎的药物中的应用 | |
| Sozo et al. | Effects of prenatal ethanol exposure on the lungs of postnatal lambs | |
| IL315941A (en) | Uses of farnesoid x receptor agonists | |
| US6348495B1 (en) | Method for treating celiac disease | |
| CN110664847A (zh) | 粪便菌群在制备治疗慢性乙型肝炎微生态制剂中的应用 | |
| JP3885135B2 (ja) | Ｃ型又は非ｂ非ｃ型肝炎ウイルスによる肝機能異常の改善剤 | |
| WO2012018145A2 (ja) | Ｑｏｌ改善剤 | |
| JP2002522507A (ja) | 疾患状態の処置 | |
| TW200940075A (en) | Agent for alleviating adverse side effects produced in interferon/ribavirin combination therapy | |
| JP2006515011A (ja) | Ｈｃｖ併用療法 | |
| Lahaye et al. | Vanishing pulmonary hypertension in mixed connective tissue disease | |
| JP3879938B2 (ja) | 抗炎症剤 | |
| JP2010208946A (ja) | 関節リウマチの予防・治療剤 | |
| JP2006515348A (ja) | 腎不全処置方法 | |
| Baird et al. | Long-duration (> 4 weeks) continuous renal replacement therapy in critical illness | |
| CN110075100A (zh) | 咖啡酸苯乙酯在制备治疗/预防高尿酸相关疾病的药物/保健品方面的应用 | |
| Chen et al. | PS-B11-7: LOSS OF C3A AND C5A RECEPTORS PROMOTES ADIPOCYTE BROWNING AND ATTENUATES DIET-INDUCED OBESITY VIA ACTIVATING INOSINE/A2AR PATHWAY | |
| Colakoğlu et al. | Effect of clonazepam on Raynaud's phenomenon and fingertip ulcers in scleroderma | |
| in't Veld et al. | Stimulated sweating in chronic renal failure |